NasdaqCM - Nasdaq Real Time Price USD

Atossa Therapeutics, Inc. (ATOS)

2.3750 +0.2050 (+9.38%)

As of 10:47:25 AM EST. Market Open.

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today

PR Newswire 14d ago

ATOS
+9.38%
Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value

PR Newswire 24d ago

ATOS
+9.38%
Atossa plans shareholder stake in potential PRV proceeds

Pharmaceutical Technology 1mo ago

ATOS
+9.38%
Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher

PR Newswire 1mo ago

ATOS
+9.38%
ATO.PA
Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging

PR Newswire 1mo ago

ATOS
+9.38%
Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

PR Newswire 2mo ago

ATOS
+9.38%
Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer

PR Newswire 3mo ago

ATOS
+9.38%
Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers

PR Newswire 3mo ago

ATOS
+9.38%
ATOS: Raises up to $16.5 Million in Registered Direct Offering

Zacks Small Cap Research 4mo ago

ATOS
+9.38%
ATO.PA
Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

PR Newswire 4mo ago

ATOS
+9.38%
Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds

PR Newswire 4mo ago

ATOS
+9.38%
Atossa Therapeutics highlights Endoxifen progress as potential Breast Cancer treatment

Proactive 4mo ago

ATOS
+9.38%

Performance Overview

Return	ATOS	S&P 500 (^GSPC)
YTD	-73.67%	+11.73%
1-Year	-82.55%	+11.82%
3-Year	-77.81%	+77.14%

U.S. markets close in 5h 12m

Atossa Therapeutics, Inc. (ATOS)

Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today

Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value

Atossa plans shareholder stake in potential PRV proceeds

Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher

Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging

Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer

Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers

ATOS: Raises up to $16.5 Million in Registered Direct Offering

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Atossa Therapeutics highlights Endoxifen progress as potential Breast Cancer treatment